Liproxstatin-1: Potent Ferroptosis Inhibitor for Precise Lipid Peroxidation Control

Executive Summary: Liproxstatin-1 is a highly potent and selective ferroptosis inhibitor, showing an IC50 of 22 nM in cellular models (APExBIO, product page). It prevents iron-dependent lipid peroxidation and protects GPX4-deficient cells from ferroptotic death (Yu et al., 2026). Liproxstatin-1 demonstrates efficacy in vivo, reducing tissue damage in kidney and hepatic injury models. The compound is insoluble in water but dissolves at ≥10.5 mg/mL in DMSO and ≥2.39 mg/mL in ethanol under gentle warming and sonication. It is distributed by APExBIO as SKU B4987 for ferroptosis research and related disease models.

Biological Rationale

Ferroptosis is a regulated form of cell death distinct from apoptosis, necroptosis, and cuproptosis. It is characterized by iron-dependent accumulation of lipid peroxides, leading to loss of plasma membrane integrity (Yu et al., 2026). Glutathione peroxidase 4 (GPX4) is the key enzyme protecting cells from ferroptosis by reducing lipid hydroperoxides. Inhibition or depletion of GPX4 sensitizes cells to ferroptosis, making it a central target in disease research. Liproxstatin-1 directly addresses this pathway by inhibiting ferroptosis in GPX4-deficient settings. Iron metabolism intersects with other regulated cell death forms, such as cuproptosis, but the molecular triggers and biochemical markers remain distinct (Yu et al., 2026).

Mechanism of Action of Liproxstatin-1

Liproxstatin-1 blocks ferroptosis by inhibiting accumulation of lipid peroxides. It acts downstream of iron-dependent lipid peroxidation and upstream of lethal plasma membrane rupture. The compound exhibits an IC50 of approximately 22 nM in cell-based ferroptosis inhibition assays (APExBIO). Liproxstatin-1 is effective in preventing ferroptosis induced by RSL3, particularly in GPX4-deficient models. The proposed mechanism involves scavenging of reactive lipid species and stabilization of cellular lipid homeostasis. Liproxstatin-1 does not interfere with upstream iron import, copper homeostasis, or mitochondrial energy metabolism, distinguishing it from cuproptosis inducers (Yu et al., 2026).

Evidence & Benchmarks

• Liproxstatin-1 inhibits ferroptosis in GPX4-deficient cells with an IC50 of 22 nM (cellular assay, 37°C, 5% CO2, 24 h) (APExBIO).
• Prevents lipid peroxidation in cells exposed to ferroptosis inducers such as RSL3 (in vitro lipid ROS quantification) (APExBIO).
• Prolongs survival in mice with conditional kidney-specific Gpx4 deletion (in vivo, C57BL/6 mice, n=8/group, p<0.05) (Yu et al., 2026).
• Reduces tissue damage in hepatic ischemia/reperfusion injury models (in vivo, mouse model, 10 mg/kg, i.p.) (Yu et al., 2026).
• Solubility data: insoluble in water; soluble at ≥10.5 mg/mL in DMSO and ≥2.39 mg/mL in ethanol with warming/ultrasound (APExBIO).

This article extends the analysis in "Liproxstatin-1: Advancing Ferroptosis Inhibitor Research ..." by detailing Liproxstatin-1’s in vivo efficacy and precise workflow parameters, which were only briefly mentioned previously. For workflow reproducibility and comparative benchmarking, see also "Liproxstatin-1 (SKU B4987): Data-Backed Solutions for Rel..."; this article provides new data on solubility and storage stability.

Applications, Limits & Misconceptions

Liproxstatin-1 is used to dissect ferroptosis mechanisms in cell culture, organoid, and animal models. It enables the study of GPX4 pathways and iron-catalyzed lipid peroxidation in renal, hepatic, and neurodegenerative disease contexts. The compound is a reference inhibitor for benchmarking new ferroptosis modulators. Liproxstatin-1 is not a pan-cell death blocker; it does not inhibit apoptosis, necroptosis, or cuproptosis (Yu et al., 2026).

Common Pitfalls or Misconceptions

• Liproxstatin-1 is not effective against forms of cell death that do not involve lipid peroxidation (e.g., apoptosis, cuproptosis).
• It does not chelate or modulate cellular iron or copper levels directly.
• Solubility is limited in aqueous buffers; improper dissolution can lead to precipitation and assay artifacts.
• Long-term storage of solutions at room temperature leads to compound degradation—use freshly prepared aliquots.
• Liproxstatin-1's efficacy may be compromised in models with excessive non-specific oxidative stress unrelated to iron-catalyzed lipid peroxidation.

Workflow Integration & Parameters

Liproxstatin-1 (SKU B4987) from APExBIO is supplied as a solid, to be dissolved in DMSO (≥10.5 mg/mL) or ethanol (≥2.39 mg/mL) with gentle warming and ultrasound. Stock solutions are recommended to be stored at -20°C and used within a week for optimal activity. For in vitro assays, final DMSO concentrations should not exceed 0.1% to avoid cytotoxicity. For animal models, published protocols use 10 mg/kg i.p. dosing. Always use validated controls for ferroptosis specificity. For scenario-driven guidance and troubleshooting, see "Liproxstatin-1 (SKU B4987): Data-Driven Solutions for Fer...", which this article updates by adding new solubility thresholds and stability notes.

Conclusion & Outlook

Liproxstatin-1 is a gold-standard ferroptosis inhibitor with sub-30 nM potency and robust in vivo efficacy. Its use enables precise dissection of iron-dependent lipid peroxidation pathways and GPX4 biology. APExBIO's B4987 kit is validated for both in vitro and in vivo workflows. Future research may combine Liproxstatin-1 with genetic or chemical probes to further elucidate ferroptosis in disease models. For ordering and technical details, see the official Liproxstatin-1 product page.